Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial

The Lancet

Volumn 378, Issue 9788, 2011, Pages 319-327

  Wherrett, Diane K ^a   Bundy, Brian ^b   Becker, Dorothy J ^c   Dimeglio, Linda A ^d   Gitelman, Stephen E ^e   Goland, Robin ^f   Gottlieb, Peter A ^g   Greenbaum, Carla J ^h   Herold, Kevan C ⁱ   Marks, Jennifer B ^j   Monzavi, Roshanak ^k   Moran, Antoinette ^l   Orban, Tihamer ^m   Palmer, Jerry P ⁿ   Raskin, Philip ^o   Rodriguez, Henry ^d   Schatz, Desmond ^p   Wilson, Darrell M ^q   Krischer, Jeffrey P ^b   Skyler, Jay S ^j  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Howard Hughes Medical Institute   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h BENAROYA RESEARCH INSTITUTE   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m JOSLIN DIABETES CENTER   (United States)

ⁿ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^p UNIVERSITY OF FLORIDA   (United States)

^q STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; C PEPTIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; INSULIN;

ADJUVANT THERAPY; ADULT; AREA UNDER THE CURVE; CANADA; CHILD; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNIZATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SCHOOL CHILD; TEST MEAL; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 79960743608     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60895-7     Document Type: Article

References (37)

1. MA Atkinson, GS Eisenbarth Type 1 diabetes: new perspectives on disease pathogenesis and treatment Lancet 358 2001 221 229 (Pubitemid 32718550)
2. JP Palmer, GA Fleming, CJ Greenbaum et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001 Diabetes 53 2004 250 264 (Pubitemid 38044724)
3. Diabetes Control and Complications Trial Research Group Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial Ann Intern Med 128 1998 517 523
4. MW Steffes, S Sibley, M Jackson et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial Diabetes Care 26 2003 832 836 (Pubitemid 36929351)
5. G Feutren, R Assan, G Karsenty for the Cyclosporin/Diabetes French Study Group Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial Lancet 328 1986 119 124
6. The Canadian-European Randomized Control Trial Group Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion Diabetes 37 1988 1574 1582
7. KC Herold, W Hagopian, JA Auger et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 2002 1692 1698 (Pubitemid 34547482)
8. B Keymeulen, E Vandemeulebroucke, AG Ziegler et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 352 2005 2598 2608 (Pubitemid 41007846)
9. MD Pescovitz, CJ Greenbaum, H Krause-Steinrauf et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 2009 2143 2152
10. T Orban, B Bundy, DJ Becker the Type 1 Diabetes TrialNet Abatacept Study Group Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial Lancet 2011 10.1016/S0140-6736(11)60886-6 published online June 28.
11. K Yamamoto, A Okamoto, K Fujio, K Yamamoto, A Okamoto, K Fujio Antigen-specific immunotherapy for autoimmune diseases Expert Opin Biol Ther 7 2007 359 367 (Pubitemid 46383478)
12. S Baekkeskov, HJ Aanstoot, S Christgau et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase Nature 347 1990 151 156
13. J Tian, M Clare-Salzler, A Herschenfeld et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice Nat Med 2 1996 1348 1353
14. R Tisch, RS Liblau, XD Yang, P Liblau, HO McDevitt Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice Diabetes 47 1998 894 899 (Pubitemid 28255662)
15. CD Agardh, CM Cilio, A Lethagen et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes J Diabetes Complications 19 2005 238 246 (Pubitemid 40910206)
16. J Ludvigsson, M Faresjo, M Hjorth et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 2008 1909 1920
17. American Diabetes Association Standards of medical care in diabetes - 2011 Diabetes Care 33 suppl 1 2011 S11 S61
18. CJ Greenbaum, T Mandrup-Poulsen, PF McGee et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes Diabetes Care 31 2008 1966 1971
19. M Solimena, F Folli, R Aparisi, G Pozza, P De Camilli Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome N Engl J Med 322 1990 1555 1560 (Pubitemid 20176695)
20. K Lan, D DeMets Discrete sequential boundaries for clinical trials Biometrika 70 1983 659 663
21. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
22. D Cox Regression model and life tables J R Stat Soc 34 1972 187 220
23. E Kaplan, P Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
24. A Agresti Categorical data analysis 1990 John Wiley & Sons New York, NY
25. X Luo, KC Herold, SD Miller Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 32 2010 488 499
26. PA Gottlieb, S Quinlan, H Krause-Steinrauf et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes Diabetes Care 33 2010 826 832
27. EH Choy, DL Scott, GH Kingsley et al. Control of rheumatoid arthritis by oral tolerance Arthritis Rheum 44 2001 1993 1997 (Pubitemid 33644040)
28. AM Faria, HL Weiner, AMC Faria, HL Weiner Oral tolerance Immunol Rev 206 2005 232 259 (Pubitemid 41105174)
29. L Chaillous, H Lefvre, C Thivolet for the Diabte Insuline Orale group Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial Lancet 356 2000 545 549 (Pubitemid 30611859)
30. P Pozzilli, D Pitocco, N Visalli et al. No effect of oral insulin on residual beta-cell function in recent-onset type 1 diabetes (the IMDIAM VII) Diabetologia 43 2000 1000 1004 (Pubitemid 30655719)
31. JS Skyler, JP Krischer, J Wolfsdorf et al. Effects of oral insulin in relatives of patients with type 1 diabetes. The diabetes prevention trial - type 1 Diabetes Care 28 2005 1068 1076 (Pubitemid 40616615)
32. JS Skyler Type 1 Diabetes TrialNet Study Group Update on worldwide efforts to prevent type 1 diabetes Ann N Y Acad Sci 1150 2008 190 196
33. AG Ziegler, GT Nepom Prediction and pathogenesis of type 1 diabetes Immunity 32 2010 468 478
34. P Achenbach, J Barker, E Bonifacio Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization Curr Diab Rep 8 2008 87 93
35. M Peakman, M von Herrath Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential Diabetes 59 2010 2087 2093
36. JB Matthews, TP Staeva, PL Bernstein, M Peakman, M von Herrath the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group Clin Exp Immunol 160 2010 176 184
37. JS Skyler, C Ricordi Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man Diabetes 60 2011 1 8